- |||||||||| clarithromycin / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: Hepys (clinicaltrials.gov) - Apr 22, 2016 P=N/A, N=2500, Not yet recruiting, N=950 --> 2500 | Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Jul 2018 --> Feb 2019
- |||||||||| nitazoxanide / Generic mfg.
Trial primary completion date: A Two Week Nitazoxanidebased Quadruple Regimen (clinicaltrials.gov) - Mar 10, 2016 P3, N=100, Recruiting, Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Sep 2016
- |||||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Enrollment closed, Trial primary completion date: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Nov 24, 2015 P3, N=840, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Feb 2016
- |||||||||| Sufenta (sufentanil) / Akorn
New trial: Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO) (clinicaltrials.gov) - Oct 22, 2015 P=N/A, N=70, Recruiting,
- |||||||||| clarithromycin / Generic mfg.
New trial: Hepys (clinicaltrials.gov) - Oct 22, 2015 P=N/A, N=950, Not yet recruiting,
|